Strategic partnerships There are active and recent partnerships with healthcare systems and digital health platforms (Pacific Cancer Care, N-Power Medicine, FamGenix, Jupiter Medical Center) indicating a track record of integration into clinical workflows. This suggests sales opportunities to expand into health systems and cancer centers seeking scalable genetic counseling and risk assessment capabilities.

Clinical workflow integration My Gene Counsel positions itself as infrastructure that connects to existing clinical workflows, lab reporting systems, and EHRs. Target buyers should include hospitals, diagnostics labs, and AI health platforms looking to embed genetic result intelligence and automated alerts into their current systems to improve result utilization.

Automated education Living Lab Reports and automated Genetic Alerts offer continuous, guideline-updated interpretations and proactive patient/provider notifications. This can be marketed to health systems and payers aiming to reduce misinterpretation risk, lower rework, and improve guideline-concordant management.

Precision medicine pilots Recent pilots and launches around precision medicine in collaboration with PCC and N-Power Medicine demonstrate appetite for ROI-driven, point-of-care genetic risk assessment. Opportunities exist to offer scalable pilot programs with larger health systems to demonstrate impact and drive broader adoption.

Market fit and scale Revenue is established in the multi-million range with a small but growing company footprint and strategic partnerships. There is potential to upsell to larger institutions and expand into oncology, lab networks, and AI health platforms seeking to integrate genetic result intelligence at scale.